The effect of 12 months' treatment with eicosapentaenoic acid in five children with cystic fibrosis.
Five children with cystic fibrosis (CF) and chronic suppurative lung disease had eicosapentaenoic acid (EPA) supplementation for 12 months. Outcome was measured by the change in frequency of admissions/bed days while taking EPA compared to the previous 2 years. Although no significant changes occurred, there is an indication that this treatment may benefit children who don't have end-stage disease. Further studies are indicated in the use of this neglected mode of treatment.
Thies
N H
NH
Warrnambool Base Hospital, Victoria, Australia.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004334:Drug Administration Schedule; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D011379:Prognosis; D012129:Respiratory Function Tests; D016896:Treatment Outcome
D015118:Eicosapentaenoic Acid